Biotech sector faces $170 billion patent cliff, drives precision oncology growth.
ByAinvest
Monday, Jan 12, 2026 10:21 am ET1min read
ALLO--
CHRS--
ONCY--
PYXS--
The biotech sector is facing a patent cliff of $170 billion, prompting a shift towards late-stage oncology platforms with biologic-like manufacturing efficiency. Precision oncology is projected to reach $225.65 billion by 2032, driving investment in proprietary precision platforms like Oncolytics Biotech, Allogene Therapeutics, Coherus Oncology, Pyxis Oncology, and Enliven Therapeutics. Accelerated approval pathways for rare oncology indications are creating commercial opportunities.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet